bimiralisib
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 25, 2019 (NCT03740100)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1- Mol. weight
- 411.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4084907 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06319794 | Phase 2 | Apr 2, 2024 | TORQUR |
| NCT03740100 | Phase 2 | Jan 25, 2019 | PIQUR Therapeutics AG, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PIQUR Therapeutics AG | For profit | 1 | 1 | 1 | 2019 |
| TORQUR | For profit | 1 | 1 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1